Phosphate mimics and methods of treatment using phosphatease inhibitors

Abstract

The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.

What is claimed:  
     
         1 . A compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 , CF 3 SO 2 NR 3 , CF 3 SO 2 R 4  or CF 3 SO 2 N(R 3 )R 4 , wherein R 3  is H, alkoxy, acyl or C 1 -C 3  alkyl, each of which may be substituted or unsubstituted, and R 4 is methylene which may be substituted or unsubstituted;  
 each R 1  is independently C 1 -C 3  alkyl, C 1 -C 3  haloalkyl, CN, (C═O)OR, (C═O)R 5 , H, halo, O(C═O)R, OR, OH, NHR, NH(C═O)OR, NH(C═O)R 5 , NO 2 , NHSO 2 R 5 , SO 2 R 5 , R 4 SO 2 CF 3  or tetrazole, wherein R 5  is CF 3 , C 1 -C 3  alkyl, NHR and wherein R is H, C 1 -C 3  alkyl, aryl or heteroaryl, which may be substituted or unsubstituted;  
 each R 2  is independently C 1 -C 3  alkyl, C 1 -C 3  haloalkyl, CN, (C═O)OR, (C═O)R 5 , H, halo, O(C═O)R, OR, OH, NHR, NH(C═O)OR, NH(C═O)R 5 , NO 2 , NHSO 2 R 5 , SO 2 R 5 , tetrazole, or X 1 —R 6 —X 2 , wherein X 1  is present or absent and if present is O, N, (C═O), (C═O)NH, NH(C═O), SO 2 NH, NHSO 2 , R 6  is C 1 -C 3  alkylene which may be substituted or unsubstituted and X 2  is CF 3 , (C═O)OR, (C═O)R 5 , H. NH(C═O)R 5 , NH(C═O)OR, NHSO 2 R 5 , NRR 3 , O(C═O)R, OR, SO 2 R 5 , tetrazole;  
 each n is independently from 0 to 3;  
 ring B is an aryl, carbocyclic, heteroaryl, heterocyclic or phenyl ring which may be substituted or unsubstituted;  
 A 1  is a linkage in which the shortest path is 2-8 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen or oxygen, or combination of nitrogen, oxygen and sulfur provided no two heteroatoms are adjacently linked in a linear linkage; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, C 1 -C 6  alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, C 1 -C 6  N-sulfonamido, C 3 -C 7  N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, ortho or para aryldioxy, substituted meta-aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C 3 -C 7  C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, disulfide, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, C 2 -C 6  S-sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, C 3 -C 6  ureido, which may be substituted or unsubstituted; and  
 A 2  is a linkage in which the shortest path is 0-6 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be single atom C, O, S or N which may be substituted or unsubstituted; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, ortho or para aryldioxy, substituted meta-aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted.  
 
     
     
         2 . The compound of  claim 1  wherein Q is CF 3 SO 2 .  
     
     
         3 . The compound of  claim 1  wherein Q is CF 3 SO 2 NR 3 .  
     
     
         4 . The compound of  claim 1  wherein Q is CF 3 SO 2 R 4 .  
     
     
         5 . The compound of  claim 1  wherein Q is CF 3 SO 2 N(R 3 )R 4 .  
     
     
         6 . The compound of  claim 1  wherein the compound has formula I.  
     
     
         7 . The compound of  claim 1  wherein the compound has formula II.  
     
     
         8 . The compound of  claim 1  wherein the compound has formula III.  
     
     
         9 . The compound of  claim 1  wherein R 2  is SO 2 R 5 , NHSO 2 R 5  or CF 3 SO 2 R 4 .  
     
     
         10 . A compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 ;  
 each R1 is independently CF3, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NHSO2R5, NO2, O(C═O)R, OH, OR, SO2R5 or tetrazole, wherein R5 is CF3, C1-C3 alkyl, NHR and wherein R is H, C1-C3 alkyl, aryl or heteroaryl, which may be, substituted or unsubstituted;  
 each R2 is independently (C═O)OR, (C═O)R5, NH(C═O)OR, NH(C═O)R5, NHR, NHSO2R5, NO2, —R6-(C═O)OR, —R6-NRR3, —R6-tetrazole, or tetrazole and R6 is C1-3 allylene which may be substituted or unsubstituted;  
 each n is independently from 0 to 2;  
 ring B is phenyl or heteroaryl which may be substituted or unsubstituted; and  
 linkage A1 is C2-C4 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, C2-C4 alkylaminoalkyl, C2-C4 alkylenediamine, C3-C4 C-amido, C3-C4 N-amido, C3-C4 ureido, C1-C3 N-sulfonamido, C2-C3 S-sulfonamido, aryldioxy, aryldiamine, aryl, alkylarylalkyl, imidazole, oxazole, oxadiazole, pyrazole, pyrazolidine, pyrrole or triazole.  
 
     
     
         11 . A compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 NR 3 , CF 3 SO 2 R 4  or CF 3 SO 2 N(R 3 )R 4 , wherein R3 is H, alkoxy, acyl or C1-C3 alkyl each of which may be substituted or unsubstituted and R4 is methylene which may be substituted or unsubstituted;  
 each R1 is independently CF3, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NHSO2R5, NO2, O(C═O)R, OH, OR, SO2R5 or tetrazole,  
 wherein R5 is CF3, C1-C3 alkyl, NHR and wherein R is H, C1-C3 alkyl, aryl or heteroaryl, which may be substituted or unsubstituted;  
 each R2 is independently (C═O)OR, (C═O)R5, NH(C═O)OR, NH(C═O)R5, NHR, NHSO2R5, NO2, SO2R5, —R6-(C═O)OR, —R6-NRR3, —R6-tetrazole, or tetrazole and R6 is C1-3 alkylene which may be substituted or unsubstituted;  
 each n is independently from 0 to 2;  
 ring B is phenyl or heteroaryl which may be substituted or unsubstituted; and  
 linkage A1 is C2-C4 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, C2-C4 alkylaminoalkyl, C2-C4 alkylenediamine, C3-C4 C-amido, C3-C4 N-amido, C3-C4 ureido, C1-C3 N-sulfonamido, C2-C3 S-sulfonamido, aryldioxy, aryldiamine, aryl, alkylarylalkyl, imidazole, oxazole, oxadiazole, pyrazole, pyrazolidine, pyrrole or triazole.  
 
     
     
         12 . A compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 ;  
 each R1 is independently H, NHR, NO2 or OR;  
 each R2 is independently (C═O)OR, NHSO2R5, or SO2R5;  
 each n is independently from 0 to 2; and the linkage A1 is alkylarylalkyl, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, aryl, aryldiamine, aryldioxy, or oxadiazole which may be substituted or unsubstituted or A1 is unsubstituted or monosubstituted C2-C4 N-amido.  
 
     
     
         13 . The compound of  claim 11  having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 R1 is H or NO2;  
 R2 is (C═O)OR, NHSO2R5 or SO2R5; and  
 the linkage A1 is C2-C4 alkoxyalkyl, aryldioxy, aryl, alkylarylalkyl or oxadiazole.  
 
     
     
         14 . The compound of  claim 12  wherein the compound is: 
 Bis(4-Trifluoromethylsulfonylbenzyl)ether;  
 4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;  
 N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;  
 1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;  
 N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzade;  
 N-(4-Trifluoromethylsulfonylbenzyl)benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-beizoic acid methyl ester;  
 [3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;  
 4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;  
 4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;  
 N-(2-Ethylamino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;  
 2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;  
 3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
 N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;  
 1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;  
 [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;  
 N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;  
 [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;  
 2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;  
 1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;  
 1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamido; or  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamido.  
 
     
     
         15 . The compound of  claim 13  wherein the compound is: 
 1,2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;  
 1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;  
 Bis(4-trifluoromethylsulfonamidophenyl)ether;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;  
 Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 4-{[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;  
 N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;  
 6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;  
 3-({6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carbonyl}-amino)-benzoic acid;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.  
 
     
     
         16 . A pharmaceutical composition comprising a compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 , CF 3 SO 2 NR 3 , CF 3 SO 2 R 4  or CF 3 SO 2 N(R 3 )R 4 , wherein R 3  is H, alkoxy, acyl or C 1 -C 3  alkyl, each of which may be substituted or unsubstituted, and R 4  is methylene which may be substituted or unsubstituted;  
 each R1 is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, O(C═O)R, OR, OH, SO2R5, R4SO2CF3 or tetrazole, wherein R5 is CF3, C1-C3 alkyl, NHR and wherein R is H, C1-C3 alkyl, aryl or heteroaryl, which may be substituted or unsubstituted;  
 each R2 is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, O(C═O)R, OR, OH, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, SO2R5, tetrazole, or X1-R6-X2 wherein X1 may be present or absent and if present is O, N, (C═O), (C═O)NH, NH(C═O), SO2NH, NHSO2;  
 R6 is C1-3 alkylene which may be substituted or unsubstituted;  
 X2 is CF3, (C═O)OR, (C═O)R5, H, NH(C═O)R5, NH(C═O)OR, NHSO2R5, NRR3, O(C═O)R, OR, SO2R5, tetrazole;  
 each n is independently from 0 to 3;  
 ring B is an aryl, carbocyclic, heteroaryl, heterocyclic or phenyl ring which may be substituted or unsubstituted;  
 A1 is a linkage in which the shortest path is 2-8 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen or oxygen, or combination of nitrogen, oxygen and sulfur provided no two heteroatoms are adjacently linked in a linear linkage; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, C1-C6 alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, C1-C6 N-sulfonamido, C3-C7 N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C3-C7 C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, disulfide, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, C2-C6 S-sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, C3-C6 ureido, which may be substituted or unsubstituted;  
 A 2  is a linkage in which the shortest path is 0-6 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be single atom C, O, S or N which may be substituted or unsubstituted; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, ortho or para aryldioxy, substituted meta-aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted.  
 
     
     
         17 . The pharmaceutical composition of  claim 16  wherein: 
 Q is CF 3 SO 2  or CF 3 SO 2 NH;  
 each R1 is independently CF3, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NHSO2R5, NO2, O(C═O)R, OH, OR, SO2R5 or tetrazole;  
 each R2 is independently (C═O)OR, (C═O)R5, NH(C═O)OR, NH(C═O)R5, NHR, NHSO2R5, NO2, SO2R5, —R6-(C═O)OR, —R6-NRR3, —R6-tetrazole or tetrazole;  
 each n is independently from 0 to 2;  
 ring B is phenyl or heteroaryl which may be substituted or unsubstituted; and  
 linkage A1 is C2-C4 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, C2-C4 alkylaminoalkyl, C2-C4 alkylenediamine, C3-C4 C-amido, C3-C4 N-amido, C3-C4 ureido, C1-C3 N-sulfonamido, C2-C3 S-sulfonamido, aryldioxy, aryldiamine, aryl, alkylarylalkyl, imidazole, oxazole, oxadiazole, pyrazole, pyrazolidine, pyrrole or triazole.  
 
     
     
         18 . The pharmaceutical composition of  claim 17  wherein the compound has the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2  or CF 3 SO 2 NH;  
 each R1 is independently H, NHR, NO2 or OR;  
 each R2 is independently (C═O)OR, or NHSO2R5 or SO2R5;  
 each n is independently from 0 to 2; and  
 the linkage A1 is alkylarylalkyl, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, aryl, aryldiamine, aryldioxy or oxadiazole.  
 
     
     
         19 . The pharmaceutical composition of  claim 16  wherein the compound is: 
 Bis(4-Trifluoromethylsulfonylbenzyl)ether;  
 4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;  
 N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;  
 1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;  
 N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzamide;  
 N-(4-Trifluoromethylsulfonylbenzyl)benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 [3,5 Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;  
 4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;  
 4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-}2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;  
 N-(2-Ethylamino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;  
 2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;  
 3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
 N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;  
 1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;  
 [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;  
 N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;  
 [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;  
 2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;  
 1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;  
 1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamido; or  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide.  
 
     
     
         20 . The pharmaceutical composition of  claim 16  wherein the compound is: 
 1,2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;  
 1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;  
 Bis(4-trifluoromethylsulfonamidophenyl)ether;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;  
 Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid,  
 4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 4-{[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indol-2-carboxylic acid ethyl ester;  
 6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;  
 N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;  
 6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;  
 3-({6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carbonyl}-amino)-benzoic acid;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.  
 
     
     
         21 . A method for treating a protein tyrosine phosphatase signal transduction associated disorder in a mammal which comprises a administering to the mammal therapeutically effective amount of a compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 , CF 3 SO 2 NR 3 , CF 3 SO 2 R 4  or CF 3 SO 2 N(R 3 )R 4 , wherein R 3  is H, alkoxy, acyl or C 1 -C 3  alkyl, each of which may be substituted or unsubstituted, and R 4  is methylene which may be substituted or unsubstituted;  
 each R1 is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, O(C═O)R, OH, OR, SO2R5, R4SO2CF3 or tetrazole, wherein R5 is CF3, C1-C3 alkyl, NHR and wherein R is H, C1-C3 alkyl, aryl or heteroaryl, which may be substituted or unsubstituted;  
 each R2 is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, O(C═O)R, OR, OH, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, SO2R5, tetrazole, or X1-R6-X2, wherein X1 may be present or absent and, if present is O, N, (C═O), (C═O)NH, NH(C═O), SO2NH, NHSO2, R6 is C1-3 alkylene which may be substituted or unsubstituted and X2 is CF3, (C═O)OR, (C═O)R5, H, NH(C═O)R5, NH(C═O)OR, NHSO2R5, NRR3, O(C═O)R, OR, SO2R5, tetrazole;  
 each n is independently from 0 to 3;  
 ring B is an aryl, carbocyclic, heteroaryl, heterocyclic or phenyl ring which may be substituted or unsubstituted;  
 A1 is a linkage in which the shortest path is 2-8 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, disulfide, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted;  
 A 2  is a linkage in which the shortest path is 0-6 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be single atom C, O, S or N which may be substituted or unsubstituted; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, ortho or para aryldioxy, substituted meta-aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, disulfide, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted  
 and a pharmaceutically acceptable carrier or excipient;  
 wherein said compound regulates, inhibits or modulates protein tyrosine phosphatase signal transduction.  
 
     
     
         22 . The method of  claim 21  wherein the protein tyrosine phosphatase signal transduction is associated with cancer, a solid tumor, glioma, melanoma, Kaposi's sarcoma, hemangioma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, liver cancer, prostate cancer, colon cancer, or epidermoid cancer.  
     
     
         23 . The method of  claim 21  wherein the protein tyrosine phosphatase signal transduction is associated with diabetes.  
     
     
         24 . The method of  claim 21  wherein the protein tyrosine phosphatase signal transduction is associated with neurological degenerative diseases.  
     
     
         25 . The method of  claim 21  wherein the protein tyrosine phosphatase signal transduction is associated with osteoporosis.  
     
     
         26 . The method of  claim 21 ,  22 ,  23 ,  24  or  25  wherein the mammal is a human.  
     
     
         27 . The method of  claim 21  wherein Q is CF 3 SO 2 .  
     
     
         28 . The method of  claim 21  wherein Q is CF 3 SO 2 NR 3 .  
     
     
         29 . The method of  claim 21  wherein Q is CF 3 SO 2 R 4 .  
     
     
         30 . The method of  claim 21  wherein Q is CF 3 SO 2 N(R 3 )R 4 .  
     
     
         31 . The method of  claim 21  wherein the compound has formula I.  
     
     
         32 . The method of  claim 21  wherein the compound has formula II.  
     
     
         33 . The method of  claim 21  wherein the compound has formula III.  
     
     
         34 . The method of  claim 21  wherein R 2  is SO 2 R 5 , NHSO 2 R 5  or CF 3 SO 2 R 4 .  
     
     
         35 . The method of  claim 21  wherein 
 Q is CF 3 SO 2  or CF 3 SO 2 NH;  
 each R1 is independently CF3, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NHSO2R5, NO2, O(C═O)R, OH, OR, SO2R5 or tetrazole;  
 each R2 is independently (C═O)OR, (C═O)R5, NH(C═O)OR, NH(C═O)R5, NHR, NHSO2R5, NO2, SO2R5, —R6-(C═O)OR, —R6-NRR3, —R6-tetrazole or tetrazole;  
 each n is independently from 0 to 2;  
 ring B is phenyl or heteroaryl which may be substituted or unsubstituted; and linkage A1 is C1-C4 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, C2-C4 alkylaminoalkyl, C2-C4 alkylenediamine, C1-C4 C-amido,-C1-C4 N-amido, C1-C4 ureido, C0-C3 N-sulfonamido, C0-C3 S-sulfonamido, aryldioxy, aryldiamine, aryl, alkylarylalkyl, imidazole, oxazole, oxadiazole, pyrazole, pyrazolidine, pyrrole or triazole.  
 
     
     
         36 . The method of  claim 21  wherein the compound has the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2  or CF 3 SO 2 NH;  
 R1 is H or NO2;  
 R2 is (C═O)OR, NHSO2R5 or SO2R5; and  
 the linkage A1 is C2-C4 alkoxyalkyl, aryldioxy, aryl, alkylarylalkyl, C1-C4 N-amido or oxadiazole.  
 
     
     
         37 . The method of  claim 21  wherein the compound is: 
 Bis(4-Trifluoromethylsulfonylbenzyl)ether;  
 4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;  
 N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;  
 1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;  
 N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzamide;  
 N-(4-Trifluoromethylsulfonylbenzyl)benzamide;  
 Bis(4-Trifluoromethylsulfonylphenyl)disulfide;  
 Bis-(2-Nitro-4-trifluoromethylsulfonylphenyl)disulfide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 [3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;  
 4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;  
 4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;  
 N-(2-Ethyl amino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;  
 2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;  
 3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
 N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;  
 1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;  
 [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;  
 N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;  
 [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;  
 2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;  
 1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;  
 1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide; or  
 Bis-{[4-(2-nitro-4-trifluoromethanesulfonyl)-phenoxy]-phenyl}sulfone.  
 
     
     
         38 . The method of  claim 21  wherein the compound is: 
 1,2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;  
 1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;  
 Bis(4-trifluoromethylsulfonamidophenyl)ether;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;  
 Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 3-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 4-}[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;  
 N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;  
 6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;  
 3-({6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carbonyl}-amino)-benzoic acid;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.  
 
     
     
         39 . A method for treating, alleviating or preventing cancer in a mammal which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 , CF 3 SO 2 NR 3 , CF 3 SO 2 R 4  or CF 3 SO 2 N(R 3 )R 4 , wherein R 3  is H, alkoxy, acyl or C 1 -C 3  alkyl, each of which may be substituted or unsubstituted, and R 4  is methylene which may be substituted or unsubstituted;  
 each R1 is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, O(C═O)R, OR, OH, SO2R5, R4SO2CF3 or tetrazole, wherein R5 is CF3, C1-C3 alkyl, NHR and wherein R is H, C1-C3 alkyl, aryl or heteroaryl, which may be substituted or unsubstituted;  
 each R2 is independently C1-3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, O(C═O)R, OR, OH, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5,SO2R5, tetrazole or X1-R6-X2, wherein X1 may be present or absent and if present is O, N, (C═O), (C═O)NH, NH(C═O), SO2NH, NHSO2, R6 is C1-3 alkylene which may be substituted or unsubstituted and X2 is CF3, (C═O)OR, (C═O)R5, H, NH(C═O)R5, NH(C═O)OR, NHSO2R5, NRR3, O(C═O)R, OR, SO2R5, tetrazole;  
 each n is independently from 0 to 3;  
 ring B is an aryl, carbocyclic, heteroaryl, heterocyclic or phenyl ring which may be substituted or unsubstituted;  
 A1 is a linkage in which the shortest path is 2-8 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen, sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyoxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, disulfide, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, or ureido which may be substituted or unsubstituted;  
 A 2  is a linkage in which the shortest path is 0-6 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be single atom C, O, S or N which may be substituted or unsubstituted; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, ortho or para aryldioxy, substituted meta-aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted;  
 and a pharmaceutically acceptable carrier or excipient.  
 
     
     
         40 . The method of  claim 39  wherein the mammal is a human.  
     
     
         41 . The method of  claim 39  wherein 
 Q is CF 3 SO 2  or CF 3 SO 2 NH;  
 each R1 is independently CF3, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NHSO2R5, NO2, O(C═O)R, OH, OR, SO2R5 or tetrazole;  
 each R2 is independently (C═O)OR, (C═O)R5, NH(C═O)OR, NH(C═O)R5, NHR, NHSO2R5, NO2, SO2R5, —R6-(C═O)OR, —R6-NRR3, —R6-tetrazole or tetrazole;  
 each n is independently from 0 to 2;  
 ring B is phenyl or heteroaryl which may be substituted or unsubstituted; and linkage A1 is C1-C4 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylenedioxy, C2-C4 alkylaminoalkyl, C2-C4 alkylenediamine, C1-C4 C-amido, C1-C4 N-amido, C1-C4 ureido, C0-C3 N-sulfonamido, C0-C3 S-sulfonamido, aryldioxy, aryldiamine, aryl, alkylarylalkyl, imidazole, oxazole, oxadiazole, pyrazole, pyrazolidine, pyrrole or triazole.  
 
     
     
         42 . The method of  claim 39  wherein the compound has the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2  or CF 3 SO 2 NH;  
 R1 is H or NO2;  
 R2 is (C═O)OR, NHSO2R5 or SO2R5; and  
 the linkage A1 is C2-C4 alkoxyalkyl, aryldioxy, aryl, alkylarylalkyl, C1-C4 N-amido or oxadiazole.  
 
     
     
         43 . The method of  claim 39  wherein the compound is: 
 Bis(4-Trifluoromethylsulfonylbenzyl)ether;  
 4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;  
 N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;  
 1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;  
 N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzamide;  
 N-(4-Trifluoromethylsulfonylbenzyl)benzamide;  
 Bis(4-Trifluoromethylsulfonylphenyl)disulfide;  
 Bis-(2-Nitro-4-trifluoromethylsulfonylphenyl)disulfide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 [3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;  
 4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;  
 4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;  
 N-(2-Ethylamino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;  
 2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;  
 3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
 N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;  
 1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;  
 [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;  
 N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;  
 [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;  
 2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;  
 1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;  
 1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide; or  
 Bis-{[4-(2-nitro-4-trifluoromethanesulfonyl)-phenoxy]-phenyl}sulfone.  
 
     
     
         44 . The method of  claim 39  wherein the compound is: 
 1,2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;  
 1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;  
 Bis(4-trifluoromethylsulfonamidophenyl)ether;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;  
 Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 4-{[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;  
 N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;  
 6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;  
 3-({6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carbonyl}-amino)-benzoic acid;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.  
 
     
     
         45 . The method of  claim 39  wherein said cancer is a solid tumor.  
     
     
         46 . The method of  claim 39  wherein said cancer is selected from the group consisting of glioma, melanoma, adenocarcinoma, Kaposi's sarcoma and hemangioma.  
     
     
         47 . The method of  claim 39  wherein said cancer is selected from the group consisting of ovarian, breast, lung, pancreatic, liver, prostate, colon, testicular, and epidermoid cancer.  
     
     
         48 . A method for regulating, inhibiting or modulating protein tyrosine phosphatase signal transduction in a cell which comprises a administering to the cell an effective amount of a compound having the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein: 
 Q is CF 3 SO 2 , CF 3 SO 2 NR 3 , CF 3 SO 2 R 4  or CF 3 SO 2 N(R 3 )R 4 , wherein R 3  is H, alkoxy, acyl or C 1 -C 3  alkyl, each of which may be substituted or unsubstituted, and R 4  is methylene which may be substituted or unsubstituted;  
 each R1is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, O(C═O)R, OR, OH, SO2R5, R4SO2CF3 or tetrazole, wherein R5 is CF3, C1-C3 alkyl, NHR and wherein R is H, C1-C3 alkyl, aryl or heteroaryl, which may be substituted or unsubstituted;  
 each R2 is independently C1-C3 alkyl, C1-C3 haloalkyl, CN, (C═O)OR, (C═O)R5, H, halo, O(C═O)R, OR, OH, NHR, NH(C═O)OR, NH(C═O)R5, NO2, NHSO2R5, SO2R5, tetrazole, or X1-R6-X2 wherein X1 may be present or absent and if present is O, N, (C═O), (C═O)NH, NH(C═O), SO2NH, NHSO2, R6 is C1-3 alkylene which may be substituted or unsubstituted and X2 is CF3, (C═O)OR, (C═O)R5, H, NH(C═O)R5, NH(C═O)OR, NHSO2R5, NRR3, O(C═O)R, OR, SO2R5, tetrazole;  
 each n is independently from 0 to 3;  
 ring B is an aryl, carbocyclic, heteroaryl, heterocyclic or phenyl ring which may be substituted or unsubstituted;  
 A1 is a linkage in which the shortest path is 2-8 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, disulfide, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted;  
 A 2  is a linkage in which the shortest path is 0-6 atoms in length wherein the atoms in the linkage are carbon which may be substituted or unsubstituted or the carbon replaced with a single nitrogen, oxygen or sulfur, or combination of nitrogen, oxygen and sulfur; the linkage may be or may contain an aryl, carbocyclic, heteroaryl, heterocyclic or a phenyl ring, which may be directly in the linkage or appended to the linkage; the linkage may be single atom C, O, S or N which may be substituted or unsubstituted; the linkage may be acylalkyl, alkenylene, alkoxy, alkoxyalkyl, alkoxyamino, alkoxyarylalkoxy, alkoxyarylalkyl, alkoxyarylamino, alkoxyaryloxyalkyl, alkylamino, alkylaminoalkyl, alkylaminoarylaminoalkyl, alkylaryl, alkylarylalkyl, alkylarylamino, alkylaryloxy, alkylene, alkylenediamine, alkylenedioxy, alkyloxy, alkyloxyaryl, alkyloxyarylalkyloxy, alkyloxyaryloxyalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkynylene, N-sulfonamido, N-amido, aminoalkyl, aminoalkylamino, aminoalkylarylalkyl, aminoalkylarylalkylamino, aminoalkylaryloxy, aminoalkyloxy, aminoaryl, aminoarylalkyl, aminoarylcarbonyl, aminoaryloxy, aminoaryloxyalkyl, aminoarylsulfonyl, aryl, arylamino, ortho or para aryldioxy, substituted meta-aryldioxy, aryldiamine, aryloxy, aryloxyalkyl, aryloxyamino, aryloxyaminoalkyl, aryloxycarbonyl, aryloxysulfonyl, benzimidazole, benzo[b]furan, benzo[b]thiophene, C-amido, carbonylarylamino, carbonylarylcarbonyl, carbonylaryloxy, chromene, cycloalkylene, furan, haloalkyl, imidazole, imidazolidine, imidazoline, indole, isothiazole, isoxazole, morpholine, oxadiazole, oxazole, oxirane, parathiazine, phenothiazine, piperazine, piperidine, purine, pyran, pyrazine, pyrazole, pyrazolidine, pyrimidine, pyridine, pyrrole, pyrrolidine, quinoline, sulfonamido, sulfonylalkyl, sulfonylarylamino, sulfonylaryloxy, sulfonylarylsulfonyl, thiadiazole, thiazole, thiophene, triazine, triazole, unsubstituted azeridine, ureido, which may be substituted or unsubstituted  
 wherein said compound regulates, inhibits or modulates protein tyrosine phosphatase signal transduction.  
 
     
     
         49 . A method for inhibiting, regulating or modulating the activity of a phosphate binding protein in a cell which comprises contacting the cell with an effective amount of a compound with a molecular weight less than 2000 daltons, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound contains at least one functional group selected from the group consisting of C(R 11 )F a SO b Z-, and R 12 SO b C(R 11 )F m —; 
 wherein a is 1, 2 or 3 and b is 1 or 2 and m is 1 or 2;  
 Z is C or N;  
 wherein R 11  is present or absent and if present is independently H, halo, C1-C4 alkyl, C 2 -C 4  alkenyl or C 1 -C 4  haloalkyl, which may be substituted or unsubstituted;  
 wherein R 12  is C1-C3 haloalkyl, C1-C3 alkyl which may be substituted or unsubstituted, or N which may be substituted or unsubstituted;  
 wherein the compound regulates, inhibits or modulates the activity of the phosphate binding protein.  
 
     
     
         50 . The method of  claim 49  wherein the compound has the formula  
       C(R 11 )F a SO b ZR 13  or R 12 SO b C(R 11 )F m R 13 ,  
       wherein ZR 13  or R 13  is an amide, an amine, an ester, an ether, a monocyclic heterocycle, a polycyclic heterocycle, an acyclic hydrocarbon, a monocyclic aliphatic hydrocarbon, a polycyclic aliphatic hydrocarbon, a monocyclic aromatic hydrocarbon, a polycyclic aromatic hydrocarbon, a macrocycle, a nucleoside, a nucleotide, an oligoamide, an oligoamine, an oligoester, an oligoether, an oligonucleotide, an oligosaccharide, an oligourea, an oligourethane, a peptide, a peptide oligomer, a saccharide, a steroid, a urea, a urethane, which may be substituted or unsubstituted.  
     
     
         51 . The method of  claim 50 , wherein the compound has the formula CF 3 SO 2 —, CF 3 SO 2 N—, CF 3 SO 2 C—, CF 3 SO 2 CO—, CF 3 SO 2 CN—, CF 3 CF 2 SO 2 — or CHF 2 SO 2 —.  
     
     
         52 . The method of  claim 51 , wherein the compound is: 
 2-[4-(Difluoro-methanesulfonyl)-phenyl]-5-naphthalen-2-yl-oxazole;    [2-Nitro-4-(1,1,2,2-tetrafluoro-ethanesulfonyl)-phenyl]-p-tolyl-amine;    Bis(4-Trifluoromethylsulfonylbenzyl)ether;    4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;    N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;    1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;    N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzamide;    N-(4-Trifluoromethylsulfonylbenzyl)benzamide;    Bis(4-Trifluoromethylsulfonylphenyl)disulfide;    Bis-(2-Nitro-4-trifluoromethylsulfonylphenyl)disulfide;    3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;    [3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;    3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;    1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;    4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;    4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;    4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;    1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;    {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;    4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;    {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;    N-(3-Trifluoromethanesulfonyl-phenyl)-2-{2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;    2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;    N-(2-Ethylamino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;    2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;    {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;    {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;    {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;    3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;    3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;    N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;    3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;    N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;    1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;    [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;    N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;    N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;    [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    [2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;    [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;    4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;    2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;    1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;    4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;    [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;    1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;    [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;    1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;    4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;    4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;    Bis-{[4-(2-nitro-4-trifluoromethanesulfonyl)-phenoxy]-phenyl}sulfone;.    1-2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;    1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;    1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;    1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;    1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;    1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;    1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;    Bis(4-trifluoromethylsulfonamidophenyl)ether;    1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;    2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;    Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;    5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;    1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;    5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;    3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;    3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;    4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;    4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;    3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol1-yl)-acetylamino]-benzoic acid;    4-{[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;    (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;    1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;    N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;    6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;    3-(6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carbonyl}-amino)-benzoic acid;    1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;    1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;    1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;    1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or    1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.    
     
     
         53 . The method of  claim 50  wherein ZR 13  or R 13  is a monocyclic heterocycle, a polycyclic heterocycle, a monocyclic aromatic hydrocarbon, a polycyclic aromatic hydrocarbon which may be substituted or unsubstituted.  
     
     
         54 . The method of  claim 49  wherein Z is methylene which may be substituted or unsubstituted.  
     
     
         55 . The method of  claim 49  wherein Z is N which may be substituted or unsubstituted.  
     
     
         56 . The method of  claim 49  wherein the molecular weight of the compound is less than 1000 daltons.  
     
     
         57 . The method of  claim 56  wherein the molecular weight of the compound is less than 650 daltons.  
     
     
         58 . The method of  claim 49  wherein the phosphate binding protein is a phophohistidine, phosphoserine, phosphothreonine or phosphotyrosine binding protein.  
     
     
         59 . The method of  claim 49  wherein the phosphate binding protein is an enzyme.  
     
     
         60 . The method of  claim 59  wherein the enzymatic phosphate binding protein forms a covalent phosphocysteine intermediate.  
     
     
         61 . The method of  claim 59  wherein the enzymatic phosphate binding protein is a metalloproteinase.  
     
     
         62 . The method of  claim 59  wherein the enzymatic phosphate binding protein is a phosphatase.  
     
     
         63 . The method of  claim 59  wherein the enzymatic phosphate binding protein is a kinase.  
     
     
         64 . The method of  claim 63  wherein the kinase is a histidine kinase, a serine kinase, a threonine kinase or a tyrosine kinase.  
     
     
         65 . The method of  claim 49  wherein the activity of the phosphate binding protein is associated with protein tyrosine phosphatase signal transduction.  
     
     
         66 . The method of  claim 49  wherein the phosphate binding protein is a dual-specificity phosphatase, a histidine/lysine phosphatase, low-molecular weight phosphatase, a phosphotyrosine binding (PTB) domain, a pleckstrin homology domain, a Ser/Thr phosphatase, a Src homology 2 (SH2) domain, a protein tyrosine phosphatase, or a tyrosine-specific phosphatase.  
     
     
         67 . The method of  claim 62  wherein the phosphatase is Alpha phosphatase, Beta phosphatase, cdc25 phosphatase, cdi phosphatase, CD45 phosphatase, DEP1 phosphatase, Epsilon phosphatase, LAR phosphatase, MAP kinase phosphatase, MEG2 phosphatase, Mu phosphatase, 1B phosphatase, PEST phosphatase, PP2 β (calcineurin) phosphatase, SHP1 phosphatase, SHP2 phosphatase, Sigma phosphatase, T-cell phosphatase, VH1-like phosphatase, VHR phosphatase, Yersinia phosphatase, or Zeta phosphatase.  
     
     
         68 . The method of  claim 49  wherein the activity of the phosphate binding protein is determined by activity in an in vitro assay.  
     
     
         69 . The method of  claim 49  wherein the cell is a mammalian cell.  
     
     
         70 . The method of  claim 69  wherein the mammalian cell is a human cell.  
     
     
         71 . A method for treating a disease, in a mammal, associated with a phosphate binding protein which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound with a molecular weight less than 2000 daltons, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound contains at least one functional group selected from the group consisting of C(R 11 )F a SO b Z-, and R 12 SO b C(R 11 )F m —; 
 wherein a is 1, 2 or 3 and b is 1 or 2 and m is 1 or 2;  
 Z is C or N;  
 wherein R 11  may be present or absent and if present is independently H, halo, C1-C4 alkyl, C 2 -C 4  alkenyl or C 1 -C 4  haloalkyl, which may be substituted or unsubstituted;  
 wherein R 12  is C1-C3 haloalkyl, C1-C3 alkyl which may be substituted or unsubstituted, or N which may be substituted or unsubstituted;  
 wherein the compound treats the disease associated with the phosphate binding protein in the mammal.  
 
     
     
         72 . The method of  claim 71 , wherein the compound has the formula CF 3 SO 2 —, CF 3 SO 2 N—, CF 3 SO 2 C—, CF 3 SO 2 CO—, CF 3 SO 2 CN—, CF 3 CF 2 SO 2 — or CHF 2 SO 2 —.  
     
     
         73 . The method of  claim 72  wherein the compound is: 
 2-[4-(Difluoro-methanesulfonyl)-phenyl]-5-naphthalen-2-yl-oxazole;  
 [2-Nitro-4-(1,1,2,2-tetrafluoro-ethanesulfonyl)-phenyl]-p-tolyl-amine;  
 Bis(4-Trifluoromethylsulfonylbenzyl)ether;  
 4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;  
 N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;  
 1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;  
 N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzamide;  
 N-(4-Trifluoromethylsulfonylbenzyl)benzamide;  
 Bis(4-Trifluoromethylsulfonylphenyl)disulfide;  
 Bis-(2-Nitro-4-trifluoromethylsulfonylphenyl)disulfide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 [3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;  
 4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;  
 4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;  
 {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;  
 N-(2-Ethylamino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;  
 2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;  
 3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;  
 3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;  
 3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;  
 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
 N-Ethyl-4-( 1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;  
 1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;  
 [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;  
 N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;  
 [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetic acid ethyl ester;  
 (2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;  
 [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;  
 {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;  
 4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;  
 2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;  
 1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;  
 1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;  
 1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;  
 4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;  
 4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;  
 Bis-{[4-(2-nitro-4-trifluoromethanesulfonyl)-phenoxy]-phenyl}sulfone;.  
 1,2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;  
 1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;  
 1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;  
 Bis(4-trifluoromethylsulfonamidophenyl)ether;  
 1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;  
 2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;  
 Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;  
 3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;  
 4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;  
 4-{[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;  
 (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;  
 1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;  
 N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;  
 6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;  
 3-({6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carbonyl}-amino)-benzoic acid;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;  
 1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or  
 1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.  
 
     
     
         74 . The method of  claim 71  wherein the phosphate binding protein is associated with cancer, a solid tumor, glioma, melanoma, Kaposi's sarcoma, hemangioma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, liver cancer, prostate cancer, colon cancer, or epidermoid cancer.  
     
     
         75 . The method of  claim 71  wherein the phosphate binding protein is associated with diabetes.  
     
     
         76 . The method of  claim 71  wherein the phosphate binding protein is associated with neurological degenerative diseases.  
     
     
         77 . The method of  claim 71  wherein the phosphate binding protein is associated with osteoporosis.  
     
     
         78 . The method of  claim 71  wherein the phosphate binding protein is associated with a lymphatic function.  
     
     
         79 . The method of  claim 76  wherein the phosphate binding protein is CD45.  
     
     
         80 . The method of  claim 71 ,  72 ,  73 ,  74 ,  75  or  76  wherein the mammal is a human.  
     
     
         81 . A method for treating cancer in a mammal which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound with a molecular weight less than 2000 daltons, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound contains at least one functional group selected from the group consisting of C(R 11 )F a SO b Z-, and R 12 SO b C(R 11 )F m —; 
 wherein a is 1, 2 or 3 and b is 1 or 2 and m is 1 or 2;  
 Z is C or N;  
 wherein R 11  may be present or absent and if present is independently H, halo, C1-C4 alkyl, C 2 -C 4  alkenyl or C 1 -C 4  haloalkyl, which may be substituted or unsubstituted;  
 wherein R is C1-C3 haloalkyl, C1-C3 alkyl which may be substituted or unsubstituted, or N which may be substituted or unsubstituted.  
 
     
     
         82 . The method of  claim 81 , wherein the compound has the formula CF 3 SO 2 —, CF 3 SO 2 N—, CF 3 SO 2 C—, CF 3 SO 2 CO—, CF 3 SO 2 CN—, CF 3 CF 2 SO 2 — or CHF 2 SO 2 —.  
     
     
         83 . The method of  claim 82 , wherein the compound is: 
 2-[4-(Difluoro-methanesulfonyl)-phenyl]-5-naphthalen-2-yl-oxazole;    [2-Nitro-4-(1,1,2,2-tetrafluoro-ethanesulfonyl)-phenyl]-p-tolyl-amine;    Bis(4-Trifluoromethylsulfonylbenzyl)ether;    4-Trifluoromethylsulfonylbenzyl 4-trifluoromethylsulfonylphenyl ether;    N,N-Bis(4-triluoromethylsulfonylbenzyl)benzamide;    1,2-Bis(4-trifluoromethylsullfonylphenyl)ethane;    N-(4-Trifluoromethylsulfonylbenzyl)-4-trifluoromethylsulfonylbenzamide;    N-(4-Trifluoromethylsulfonylbenzyl)benzamide;    Bis(4-Trifluoromethylsulfonylphenyl)disulfide;    Bis-(2-Nitro-4-trifluoromethylsulfonylphenyl)disulfide;    3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;    [3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester;    3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;    1,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-cyclopentane;    4-Methyl-2,6-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzoic acid methyl ester;    4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid methyl ester;    4-[3-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;    1-(3,5-Bis-trifluoromethyl-phenyl)-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-1H-pyrazole-3-carboxylic acid methyl ester;    {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;    4-[3-(4-Trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid;    {4-[4-(4-Trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid ethyl ester;    N-(3-Trifluoromethanesulfonyl-phenyl)-2-{2-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(3-Trifluoromethanesulfonyl-phenyl)-2-{3-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(3-Trifluoromethanesulfonyl-phenyl)-2-{4-[(3-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    3,6-Bis-(morpholin-4-ylmethyl)-2,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzene;    [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-dimethyl-amine;    N-(2-Ethylamino-5-trifluoromethanesulfonyl-phenyl)-2-(4-methanesulfonyl-phenyl)-acetamide;    2-Hydroxy-5-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;    {2-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;    {3-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;    {4-[(3-Trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetic acid;    3,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-benzamide;    3,5-Bis-(4-trifluoromethanesulfonyl-phenoxy)-benzoic acid;    N-(4-Trifluoromethanesulfonyl-phenyl)-2-{2-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(4-Trifluoromethanesulfonyl-phenyl)-2-{3-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    N-(4-Trifluoromethanesulfonyl-phenyl)-2-{4-[(4-trifluoromethanesulfonyl-phenylcarbamoyl)-methyl]-phenyl}-acetamide;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid methyl ester;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoic acid;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-pyridin-4-yl-benzamide;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(4-methoxy-phenyl)-benzamide;    3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzoylamino]-benzoic acid ethyl ester;    4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;    N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazol-2-yl)-benzamide;    1-Ethyl-5-trifluoromethanesulfonyl-1H-benzoimidazole-2-carboxylic acid;    [2-(Benzoyl-butyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid methyl ester;    N-Benzyl-N-[butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;    N-[Butylcarbamoyl-(4-trifluoromethanesulfonyl-phenyl)-methyl]-N-(2-hydroxy-ethyl)-benzamide;    [2-(Acetyl-cyclopropyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    [2-(Acetyl-methyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester; [2-(Benzoyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    N-Cyclohexyl-N-[(2,6-dimethyl-phenylcarbamoyl)-(4-trifluoromethanesulfonyl-phenyl)-methyl]-benzamide;    [2-(Acetyl-propyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    [2-(Acetyl-cyclohexyl-amino)-2-(4-trifluoromethanesulfonyl-phenyl)-acetylamino]-acetic acid ethyl ester;    {4-[4-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-benzenesulfonyl]-phenoxy}-acetic acid;    4-[2-(2-Nitro-4-trifluoromethanesulfonyl-phenoxy)-ethoxy]-benzoic acid;    2,5-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-terephthalic acid diethyl ester;    1-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-piperidine;    4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-morpholine;    [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(2-nitro-phenyl)-amine;    1-(2-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;    [2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propyl]-(4-nitro-phenyl)-amine;    1-(4-Nitro-phenylamino)-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propan-2-ol;    4-[2-Hydroxy-3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;    4-[2,3-Bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-propylamino]-benzenesulfonamide;    Bis-{[4-(2-nitro-4-trifluoromethanesulfonyl)-phenoxy]-phenyl}sulfone;.    1,2-Bis(4-trifluoromethylsulfonamidophenyl)ethane;    1,2-Bis(2-methyl-4-trifluoromethylsulfonamidophenyl)ethane;    1,3-Bis(4-trifluoromethylsulfonamidophenoxy)-2,2-dimethylpropane;    1,3-Bis(4-trifluoromethylsulfonamidophenoxy)propane;    1,4-Bis(4-trifluoromethylsulfonamidophenoxy)butane;    1,4-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;    1-(4-Aminophenoxy)-4-trifluoromethylsulfonamidophenoxy benzene;    Bis(4-trifluoromethylsulfonamidophenyl)ether;    1,3-Bis(4-trifluoromethylsulfonamidophenoxy)benzene;    2,5-Bis(4-trifluoromethylsulfonamidophenyl)-(1,3,4)oxadiazole;    Bis(4-trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene;    5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid;    1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;    5-Trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid phenylamide;    3-[(1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;    3-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;    4-[(5-Trifluoromethanesulfonylamino-1H-indole-2-carbonyl)-amino]-benzoic acid;    4-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;    3-[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-benzoic acid;    4-{[2-(2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetylamino]-methyl}-benzoic acid;    (2-Methyl-5-trifluoromethanesulfonylamino-indol-1-yl)-acetic acid tert-butyl ester;    1-Methyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    6-Trifluoromethanesulfonylamino-naphthalene-2-carboxylic acid;    N,N-Bis[(6-carboxyl-naphthalen-2-yl)methyl]trifluoromethanesulfonamide;    6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl]-naphthalene-2-carboxylic acid;    3-({6-[(Methyl-trifluoromethanesulfonyl-amino)-methyl] -naphthalene-2-carbonyl}-amino)-benzoic acid;    1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    1-tert-Butoxycarbonylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    1-Carboxymethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid;    1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;    1-tert-Butoxycarbonylmethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid ethyl ester;    1-Carboxymethyl-5-(N,N-ditrifluoromethanesulfonyl)amino-1H-indole-2-carboxylic acid;    1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid ethyl ester;    1-Benzyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid; or    1-Cyclohexylmethyl-5-trifluoromethanesulfonylamino-1H-indole-2-carboxylic acid.    
     
     
         84 . The method of  claim 81  wherein the mammal is a human.  
     
     
         85 . The method of  claim 81  wherein the cancer is a solid tumor.  
     
     
         86 . The method of  claim 84  wherein the cancer is glioma, melanoma, adenocarcinoma, Kaposi's sarcoma or hemangioma.  
     
     
         87 . The method of  claim 81  wherein the cancer is ovarian, breast, lung, pancreatic, liver, prostate, colon, testicular or epidermoid cancer.  
     
     
         88 . A method for preventing cancer in a mammal which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound with a molecular weight less than 2000 daltons, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound contains at least one functional group selected from the group consisting of C(R 11 )F a SO b Z-, and R 12 SO b C(R 11 )F m —; 
 wherein a is 1, 2 or 3 and b is 1 or 2 and m is 1 or 2;  
 Z is C or N;  
 wherein R 11  may be present or absent and if present is independently H, halo, C1-C4 alkyl, C 2 -C 4  alkenyl or C 1 -C 4  haloalkyl, which may be substituted or unsubstituted;  
 wherein R 12  is C1-C3 haloalkyl, C 1 -C3 alkyl which may be substituted or unsubstituted, or N which may be substituted or unsubstituted.  
 
     
     
         89 . A method of inhibiting phosphatase activity which comprises contacting a mammalian cell having a phosphatase with a compound having a molecular weight of less than 2000 daltons, wherein said compound is a non-ionic trifluoromethylsulfonyl or trifluoromethyl sulfonamide compound.